Lupin Limited has received approval for its Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, from the United States Food and Drug Administration to market a generic equivalent of Truvada Tablets, 200 mg/300 mg, of Gilead Sciences, Inc. 

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection and will be manufactured at Lupin's facility in Nagpur. 

The drug will also be used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. 

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021. 

Lupin is an innovation-led transnational pharmaceutical company and enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal, central nervous system and women’s health areas. The company has invested 9.6% of its revenue on research and development in FY21. 

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the biotechnology & pharmaceuticals sector.